Tag: SPACs
SPAC Trend Gives Rise to Securities Enforcement and Litigation Risks
What is a SPAC Special purpose acquisition companies (SPACs) are on the rise. A SPAC is a publicly traded shell company with no underlying operating business that seeks to merge with a target operating company. According to Nasdaq, in 2015, SPACs made up approximately 12% of the IPO market, but by […]
Corp Fin Issues Disclosure Guidance on SPACs
Happy new year! To complete the year- and term-end surge, just before Christmas, the Corp Fin staff issued CF Disclosure Guidance: Topic No. 11 regarding disclosure considerations for special purpose acquisition companies in connection with their IPOs and subsequent business combinations, often referred to as de-SPAC transactions. As usual, the […]
Highlights from Cooley’s M&A Dealmakers Roundtable: SPACs!
On September 24, Cooley M&A partner, Garth Osterman, moderated a webinar on the current trend in going public: SPACs! Dave Peinsipp, co-chair of Cooley’s capital markets practice group and Rama Padmanabhan, a Cooley M&A partner participated in the webinar which focused on the current wave of SPAC activity and how […]
SPAC Transactions – Considerations for Target-Company CFOs
Although special-purpose acquisition companies (SPACs) have been used for decades as alternative investment vehicles, they have recently come into vogue as seasoned investors and management teams have turned to SPACs to mitigate the increased market volatility risk of traditional initial public offerings (IPOs). In fact, 2020 has been a record-breaking […]
A Couple of Quick Items Regarding IPO Alternatives
Here are two quick items regarding popular IPO alternatives, SPACs (special purpose acquisition corporations) and primary direct listings: SPACs. In an interview on CNBC with Andrew Ross Sorkin on Thursday, SEC Chair Jay Clayton addressed the recent SPAC frenzy. (Very loosely, SPACs are companies with no real operations formed to […]
Past Event: Cell & Gene Meeting on The Mesa
The Cell & Gene Meeting on the Mesa is the sector’s foremost annual conference bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. This conference covers commercialization hurdles facing the cell and gene therapy sector as well as a wide range of topics […]
Past Event: Bay Area IPO Readiness Workshop
Cooley partner Dave Peinsipp, Deloitte and leaders from other organizations well-versed in the IPO, direct listing and SPAC processes shared their insights on the next normal. Topics include Current market conditions Regulatory considerations How to prepare for the IPO process Life as a public company Actionable insights from a CFO/controller […]
Past Event: The 2020 IPO Comeback Series
After IPO issuances came to a near-halt in late Q1 and early Q2 2020, the window reopened wide this summer when much-needed liquidity infused the markets and led to one of the strongest months for IPOs in 13 years. This two-part executive webinar series was on the novel challenges of […]